Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5 Suppl B
|
pubmed:dateCreated |
1987-12-4
|
pubmed:abstractText |
The Thrombolysis in Myocardial Infarction (TIMI) Study Group is investigating whether percutaneous transluminal coronary angioplasty or intravenous beta-receptor blockers, or both, are useful adjuncts to recombinant tissue-type plasminogen activator (rt-PA) in the treatment of patients with acute myocardial infarction (TIMI II study). A total of 317 patients with acute myocardial infarction were treated an average of 2.7 hours after the onset of chest pain during the course of a nonrandomized pilot investigation with 150 mg of rt-PA given over 6 hours. This dose of rt-PA resulted in a high rate of infarct-related coronary artery patency (82 and 87% of patients catheterized an average of either 1 or 32 hours after entry, respectively) and a low 21 day mortality rate of 4.4%. Coronary angioplasty was performed successfully in greater than 90% of patients with appropriate anatomy and in greater than 50% of those treated with rt-PA. In 75 patients treated within 2 hours of the onset of chest pain only 2 (2.7%) were dead by 6 weeks. However, five cases of intracranial hemorrhage were noted, and the rt-PA dose was subsequently reduced to 100 mg given over 6 hours. The TIMI II design and the results of the TIMI II pilot study are discussed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0735-1097
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
51B-64B
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2889758-Adrenergic beta-Antagonists,
pubmed-meshheading:2889758-Angioplasty, Balloon,
pubmed-meshheading:2889758-Combined Modality Therapy,
pubmed-meshheading:2889758-Coronary Angiography,
pubmed-meshheading:2889758-Coronary Vessels,
pubmed-meshheading:2889758-Drug Evaluation,
pubmed-meshheading:2889758-Exercise Test,
pubmed-meshheading:2889758-Heart Catheterization,
pubmed-meshheading:2889758-Heart Ventricles,
pubmed-meshheading:2889758-Humans,
pubmed-meshheading:2889758-Myocardial Infarction,
pubmed-meshheading:2889758-Pilot Projects,
pubmed-meshheading:2889758-Random Allocation,
pubmed-meshheading:2889758-Recombinant Proteins,
pubmed-meshheading:2889758-Time Factors,
pubmed-meshheading:2889758-Tissue Plasminogen Activator
|
pubmed:year |
1987
|
pubmed:articleTitle |
The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
|
pubmed:affiliation |
Maryland Medical Research Institute, Inc., Baltimore 21210.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|